MTORC1/2 and HDAC1/2 inhibition promote tumor response through inhibition of MYC

被引：0
|
作者：
DeStefanis, Rebecca A. [1 ]
Olson, Autumn M. [1 ]
DeZeeuw, Alyssa K. [1 ]
Payne, Susan N. [1 ]
Pasch, Cheri A. [1 ]
Clipson, Linda [1 ]
Deming, Dustin A. [1 ]
机构：
[1] Univ Wisconsin Madison, Madison, WI USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1128
引用
收藏
页数：2
相关论文
共 50 条
  • [1] MTORC1/2 and HDAC1/2 inhibition as therapy for colorectal cancer with PIK3CA mutation
    Olson, Autumn M.
    DeStefanis, Rebecca A.
    DeZeeuw, Alyssa K.
    Payne, Susan N.
    Pasch, Cheri A.
    Clipson, Linda
    Deming, Dustin A.
    CANCER RESEARCH, 2022, 82 (12)
  • [2] Inhibition of mTORC1 by dihydroartemisinin
    Liu, Wang
    Luo, Jun
    Odaka, Yoshinobu
    Huang, Shile
    CANCER RESEARCH, 2020, 80 (16)
  • [3] Inhibition of human immunodeficiency virus type 1 by niclosamide through mTORC1 inhibition
    Niyomdecha, Nattamon
    Suptawiwat, Ornpreya
    Boonarkart, Chompunuch
    Jitobaom, Kunlakunya
    Auewarakul, Prasert
    HELIYON, 2020, 6 (06)
  • [4] Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer
    Korets, Sharmilee Bansal
    Musa, Fernanda
    Curtin, John
    Blank, Stephanie V.
    Schneider, Robert J.
    GYNECOLOGIC ONCOLOGY, 2014, 132 (02) : 468 - 473
  • [5] Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition
    Niamh Coleman
    Vivek Subbiah
    Shubham Pant
    Keyur Patel
    Sinchita Roy-Chowdhuri
    Sireesha Yedururi
    Amber Johnson
    Timothy A. Yap
    Jordi Rodon
    Kenna Shaw
    Funda Meric-Bernstam
    npj Precision Oncology, 5
  • [6] Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition
    Coleman, Niamh
    Subbiah, Vivek
    Pant, Shubham
    Patel, Keyur
    Roy-Chowdhuri, Sinchita
    Yedururi, Sireesha
    Johnson, Amber
    Yap, Timothy A.
    Rodon, Jordi
    Shaw, Kenna
    Meric-Bernstam, Funda
    NPJ PRECISION ONCOLOGY, 2021, 5 (01)
  • [7] Dual mTORC1/mTORC2 inhibition limits tumor growth, VEGF production and vascular regrowth
    Barr, Sharon
    Falcon, Beverly L.
    Ghokale, Prafulla C.
    Chou, Jeyling
    Fogarty, Jennifer
    Depeille, Philippe
    Miglarese, Mark
    Epstein, David M.
    CLINICAL CANCER RESEARCH, 2012, 18 (10)
  • [8] mTORC1/2 inhibition as a treatment strategy for subtypes of colorectal cancer
    Fricke, Stephanie
    Pasch, Cheri
    Payne, Susan
    Yueh, Alexander
    Foley, Tyler
    Korkos, Demetra
    Van De Hey, Dana
    Clipson, Linda
    Deming, Dustin
    CANCER RESEARCH, 2016, 76
  • [9] Targeted therapy for mTORC1-driven tumours through HDAC inhibition by exploiting innate vulnerability of mTORC1 hyper-activation
    Fuchun Yang
    Shaogang Sun
    Chenran Wang
    Michael Haas
    Syn Yeo
    Jun-Lin Guan
    British Journal of Cancer, 2020, 122 : 1791 - 1802
  • [10] Targeted therapy for mTORC1-driven tumours through HDAC inhibition by exploiting innate vulnerability of mTORC1 hyper-activation
    Yang, Fuchun
    Sun, Shaogang
    Wang, Chenran
    Haas, Michael
    Yeo, Syn
    Guan, Jun-Lin
    BRITISH JOURNAL OF CANCER, 2020, 122 (12) : 1791 - 1802
12345